51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
17 citations
,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
January 2017 in “Elsevier eBooks” Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.
February 2020 in “Bulletin of Experimental Biology and Medicine” Finasteride and GIZh-72 reduce inflammation, with GIZh-72 being more effective.
July 2024 in “Reactions Weekly”
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
August 2025 in “Journal of the American Academy of Dermatology”
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
6 citations
,
July 2025 in “Cancer Medicine” The study investigated ZSYY001, a polymeric micellar paclitaxel formulation, in preclinical and phase I trials for advanced solid tumors. Preclinical tests on xenograft models showed significant tumor growth inhibition without weight loss. In the phase I trial, involving 18 patients, ZSYY001 was administered at doses up to 390 mg/m² without premedication, and no dose-limiting toxicities were observed. Common side effects included anemia and hair loss, but no acute hypersensitivity reactions occurred. The study found two partial responses and seven cases of stable disease, indicating promising antitumor activity. ZSYY001 was deemed safe, well-tolerated, and exhibited non-linear pharmacokinetics, suggesting it as a potential treatment option.
13 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
5 citations
,
January 2021 in “Frontiers in Cell and Developmental Biology” Inhibiting Zyxin may help treat androgenetic alopecia by promoting hair growth.
September 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Reducing Zyxin may help treat hair loss.
169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
9 citations
,
August 2024 in “Journal of Orthopaedic Translation” Strontium zinc silicate may help treat osteoporosis and muscle loss.
2 citations
,
January 2004 in “Linchuang pifuke zazhi” ZD1839 can cause skin issues like acne and hair changes.
12 citations
,
June 2024 in “JAAD Case Reports” Tirzepatide may improve hair loss by reducing insulin resistance.
15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.